U.S. lab‑labels market growth

A market report is projecting years of growth for U.S. healthcare and laboratory labels, a small product category tied to specimen tracking, device identification, and cold-chain shipping. (strategicpackaginginsights.com) One widely circulated 2026 forecast put the broader healthcare and laboratory labels market at $8.5 billion in 2024 and projected it to reach $13.2 billion by 2033, a 5.2% compound annual growth rate. The report breaks the market into hospitals, diagnostic laboratories, research institutes, pharmaceuticals, and medical devices. (strategicpackaginginsights.com) In plain terms, these labels are the printed IDs on blood tubes, specimen containers, device packages, and shipping packs that let people and scanners tell one item from another. The Clinical and Laboratory Standards Institute has long published a bar-code standard for specimen container identification used in clinical laboratories and automated systems. (clsi.org) Federal rules already make labeling a compliance issue, not just a packaging choice. The Food and Drug Administration’s Unique Device Identification rule says the label of every medical device, and every device package, must bear a unique device identifier, with listed exceptions. (ecfr.gov) The Food and Drug Administration also maintains guidance and training for companies on Unique Device Identification, including form-and-content guidance issued in 2021 and updated compliance policy for some Class I and unclassified devices issued in 2022. A draft guidance on identifier requirements for combination products was added on June 26, 2025. (fda.gov) Labs and hospitals are also using labels in places where temperature and transport rules are strict. The Centers for Disease Control and Prevention defines the cold chain as a temperature-controlled supply chain that runs from manufacturing through transport, storage, and use, and its specimen-shipping guidance tells submitters to label, mark, and document packages before shipment. (cdc.gov; cdc.gov) That demand is tied to error reduction as much as regulation. The Centers for Disease Control and Prevention’s Laboratory Medicine Best Practices workgroup says barcoding systems for specimen labeling are an evidence-based best practice with high overall strength of evidence for reducing identification errors. (cdc.gov) Published research has described specimen identification errors as a leading source of laboratory mistakes, and one review found barcoding reduced patient-specimen and testing identification errors across hospital settings. Another patient-safety review said mislabeled specimens can lead to delayed treatment, unnecessary recollection, and harm. (pmc.ncbi.nlm.nih.gov; pmc.ncbi.nlm.nih.gov) Some of the growth story is also about tougher use cases. The labels on a freezer-stored sample, a courier-shipped infectious specimen, or a machine-read blood tube have to stay legible through moisture, abrasion, low temperatures, and repeated handling. (who.int; clsi.org) So the market forecast is less about stickers than about infrastructure: every extra sample, device, and shipment adds another point where a printed identifier has to survive long enough to be trusted by a person or a scanner. (ecfr.gov; cdc.gov)